Although we regard TBK1 as one of the most promising targets for the treatment of ALS, it is essential to emphasize the significant value of TNFSF12, RESP18, and GPX3 in ALS drug research as well. This evidence concerns the gene RESP18 and amyotrophic lateral sclerosis.